[go: up one dir, main page]

ATE414535T1 - Trägerproteine für impfstoffe - Google Patents

Trägerproteine für impfstoffe

Info

Publication number
ATE414535T1
ATE414535T1 AT04776921T AT04776921T ATE414535T1 AT E414535 T1 ATE414535 T1 AT E414535T1 AT 04776921 T AT04776921 T AT 04776921T AT 04776921 T AT04776921 T AT 04776921T AT E414535 T1 ATE414535 T1 AT E414535T1
Authority
AT
Austria
Prior art keywords
carrier proteins
vaccines
based vaccines
antigen
things
Prior art date
Application number
AT04776921T
Other languages
English (en)
Inventor
John Kim
Francis Michon
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Application granted granted Critical
Publication of ATE414535T1 publication Critical patent/ATE414535T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04776921T 2003-06-23 2004-06-23 Trägerproteine für impfstoffe ATE414535T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48040903P 2003-06-23 2003-06-23

Publications (1)

Publication Number Publication Date
ATE414535T1 true ATE414535T1 (de) 2008-12-15

Family

ID=33551917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04776921T ATE414535T1 (de) 2003-06-23 2004-06-23 Trägerproteine für impfstoffe

Country Status (12)

Country Link
US (1) US7972608B2 (de)
EP (1) EP1638601B1 (de)
JP (1) JP4764820B2 (de)
KR (2) KR101206544B1 (de)
AT (1) ATE414535T1 (de)
AU (1) AU2004251726B2 (de)
BR (1) BRPI0411854A (de)
CA (1) CA2530363C (de)
DE (1) DE602004017864D1 (de)
ES (1) ES2317043T3 (de)
MX (1) MXPA05014016A (de)
WO (1) WO2005000346A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5814494B2 (ja) 2002-11-12 2015-11-17 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ感染に対する多糖類ワクチン
GB0522303D0 (en) * 2005-11-01 2005-12-07 Chiron Srl Culture method
CL2007000839A1 (es) * 2006-03-30 2008-01-25 Glaxosmithline Biolog S A Procedimiento para producir un conjugado que comprende un polisacárido u oligosacárido de tipo 5 u 8 de s. aureus y una proteína portadora; conjugado inmunogénico que lo comprende; vacuna que comprende al conjugado; procedimiento de obtención de dicha vacuna; y uso del conjugado para tratar o prevenir la infección por estafilococos
US20100021503A1 (en) * 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
US8492364B2 (en) 2008-07-21 2013-07-23 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic β-1,6 glucosamine oligosaccharides
MX338753B (es) * 2009-09-30 2016-04-29 Novartis Ag Conjugacion de polisacaridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
CN109134677A (zh) 2009-10-30 2019-01-04 诺华股份有限公司 金黄色葡萄球菌5型和8型荚膜多糖的纯化
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
CN102869778B (zh) 2010-03-30 2015-05-20 菲尼克斯公司 重组毒素蛋白的高水平表达
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
CN102809655B (zh) * 2012-08-26 2014-05-21 玉溪沃森生物技术有限公司 一种脑膜炎球菌多糖结合疫苗成品各群多糖含量的测定方法
RU2015106791A (ru) 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са Иммуногенные композиции
EP2724730A1 (de) 2012-10-29 2014-04-30 Institut Pasteur Glycokonjugate und deren Verwendung als potentielle Impfstoffe gegen Infektion durch Shigella flexneri
WO2014147287A1 (en) 2013-03-21 2014-09-25 Jukka Seppälä Nanocrystalline cellulose (ncc) as an antiviral compound
WO2016001762A1 (en) 2014-07-02 2016-01-07 Spherium Biomed S.L. Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc)
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3292146A1 (de) * 2015-05-04 2018-03-14 Pfizer Inc Gruppe-b-streptococcus-polysaccharid-proteinkonjugate, verfahren zur herstellung von konjugaten, immunogene zusammensetzungen mit konjugaten und verwendungen davon
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018229708A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
CN114728051A (zh) 2019-11-22 2022-07-08 葛兰素史克生物有限公司 细菌糖糖缀合物疫苗的剂量和施用
EP4234572A4 (de) * 2020-10-20 2024-09-25 Shanghai Reinovax Biologics Co., Ltd Proteoglykankonjugat und anwendung davon
EP4247828A1 (de) 2020-11-20 2023-09-27 Institut Pasteur Geschützte disaccharide, verfahren zu ihrer herstellung und ihre verwendung zur synthese zwitterionischer oligosaccharide und konjugate davon

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062905A (en) * 1976-08-02 1977-12-13 Mobil Oil Corporation Manufacture of light olefins
US4079095A (en) * 1976-11-04 1978-03-14 Mobil Oil Corporation Manufacture of light olefins
US4310440A (en) * 1980-07-07 1982-01-12 Union Carbide Corporation Crystalline metallophosphate compositions
US4440871A (en) * 1982-07-26 1984-04-03 Union Carbide Corporation Crystalline silicoaluminophosphates
US4677242A (en) * 1982-10-04 1987-06-30 Union Carbide Corporation Production of light olefins
US4677243A (en) * 1982-10-04 1987-06-30 Union Carbide Corporation Production of light olefins from aliphatic hetero compounds
US4499327A (en) * 1982-10-04 1985-02-12 Union Carbide Corporation Production of light olefins
US4673559A (en) * 1983-12-19 1987-06-16 Mobil Oil Corporation Silicoaluminophosphate crystallization using hydrolysis
US5047141A (en) * 1984-07-16 1991-09-10 Mobil Oil Corporation Larger pore molecular sieves of controlled activity
US4873390A (en) * 1987-07-07 1989-10-10 Uop Chemical conversion process
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5141729A (en) * 1988-04-08 1992-08-25 Mobil Oil Corporation Synthesis of crystalline metalloaluminophosphate composition
GB8914122D0 (en) * 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5095163A (en) * 1991-02-28 1992-03-10 Uop Methanol conversion process using SAPO catalysts
EP0568913A3 (de) * 1992-05-03 1995-03-22 Dalian Chemical Physics Inst Verfahren zur Umwandlung von Methanol in leichte Olefine und dafür verwendeter Katalysator.
EP0667787B1 (de) * 1992-09-24 2001-07-18 Brigham And Women's Hospital Gruppe b streptococcus typ ii und typ v polysaccharid-protein konjugate als impfstoffe
ATE215124T1 (de) * 1993-07-30 2002-04-15 Medeva Holdings Bv Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
US6284884B1 (en) * 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
WO1999007839A2 (en) * 1997-08-05 1999-02-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
GB9720033D0 (en) * 1997-09-19 1997-11-19 Medeva Plc Hepatitis B virus polypeptides
US6482998B1 (en) * 1998-04-29 2002-11-19 Exxonmobil Chemical Patents, Inc. Process for converting oxygenates to olefins with direct product quenching for heat recovery
US6166282A (en) * 1999-08-20 2000-12-26 Uop Llc Fast-fluidized bed reactor for MTO process
GB0009470D0 (en) * 2000-04-17 2000-06-07 Univ Southampton Materials and methods relating to immune responses to fusion proteins
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines

Also Published As

Publication number Publication date
JP4764820B2 (ja) 2011-09-07
US20070014812A1 (en) 2007-01-18
BRPI0411854A (pt) 2006-08-29
KR101206544B1 (ko) 2012-11-30
WO2005000346A1 (en) 2005-01-06
MXPA05014016A (es) 2006-03-17
CA2530363C (en) 2013-05-07
KR20060041184A (ko) 2006-05-11
CA2530363A1 (en) 2005-01-06
AU2004251726B2 (en) 2010-01-28
EP1638601B1 (de) 2008-11-19
DE602004017864D1 (de) 2009-01-02
KR101318320B1 (ko) 2013-10-15
JP2007524621A (ja) 2007-08-30
AU2004251726A1 (en) 2005-01-06
US7972608B2 (en) 2011-07-05
ES2317043T3 (es) 2009-04-16
KR20120101580A (ko) 2012-09-13
EP1638601A1 (de) 2006-03-29

Similar Documents

Publication Publication Date Title
ATE414535T1 (de) Trägerproteine für impfstoffe
ATE554107T1 (de) Als therapeutika geeignete monovalente antikörperfragmente
ATE461220T1 (de) Anti-egfr-antikörper
TW200510459A (en) RG1 antibodies and uses thereof
CY1109683T1 (el) Αντιγονα του streptococcus pyogenes
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
CY1116913T1 (el) Τροποποιημενα κλασματα fab αντισωματων
CY1117963T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
CY1119106T1 (el) Αντισωματα εναντι masp-2
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
TW200732349A (en) Anti-OX40L antibodies and methods using same
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
NO20063624L (no) FC region varianter
TW200626171A (en) Fixed dosing of HER antibodies
ATE424560T1 (de) Marker für neuromyelitis optica
EA200702193A1 (ru) Гликозилирование белков
DK2097453T3 (da) Monoklonale antistoffer mod humant Anti-Müllerian Hormon type II receptor (AMHR-II)
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
CY1105980T1 (el) Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
DE60025704D1 (de) Das goodpasture-antigen bindende protein
DE602004018155D1 (de) Einen grössenausschlussschritt verwendendes verbessertes bisulfit-verfahren
ATE449177T1 (de) Staphylococcus epidermidis antigene

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties